ArticleBioengineered2021

Fully human recombinant antibodies against EphA2 from a multi-tumor patient immune library suitable for tumor-targeted therapy.

Yaqi Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.